Recursion Pharmaceuticals (NasdaqGS:RXRX) reported positive early clinical data from its AI driven drug discovery programs. The company highlighted progress in oncology and rare disease candidates in ...
In recent days, Recursion Pharmaceuticals reported positive early clinical data and advances in its AI-driven drug discovery pipeline, alongside a narrower-than-expected first-quarter EPS loss and ...
SAN FRANCISCO--(BUSINESS WIRE)--Splunk Inc. (NASDAQ: SPLK), first in delivering “aha” moments from machine data, today announced biotechnology company Recursion Pharmaceuticals is using Splunk® ...
SALT LAKE CITY--(BUSINESS WIRE)--Imran S. Haque, Ph.D., a computer scientist by training, has made a name for himself at the intersection of machine learning and biology by maintaining a high standard ...
Bayer and digital biology company Recursion Inc. entered into a strategic collaboration agreement to leverage Recursion’s purpose-built, artificial intelligence-guided drug discovery platform and ...
Recursion Pharmaceuticals (NASDAQ:RXRX) has experienced notable share price fluctuations in 2025, falling 27% year-to-date and trading over 55% beneath its 52-week high of $12. In spite of this ...
Opinion
2dOpinion
When AI Builds Itself: Why Recursive Self-Learning Is the Most Important Concept in Financial Servic
Most financial services executives still encounter AI as a product feature: a better chatbot, a faster credit model, a smarter fraud flag. These are valuable, but they are fundamentally static. Humans ...
In The Lancet in 1971, Julian Tudor Hart gave medicine one of its most important insights: the availability of medical care ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results